[
  {
    "text":"RLF-100 (aviptadil) clinical trial  showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells. - Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites. - Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes. - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol. RADNOR, Pa. and GENEVA , Aug. 2, 2020 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) \"Relief\" today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes."
  },
  {
    "text":"Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test. MINNEAPOLIS and NEW YORK , Aug. 3, 2020 /PRNewswire/ --\u00a0Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York , through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available for research use in early August."
  },
  {
    "text":"AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management. IRVINE, Calif. , Aug. 3, 2020 /PRNewswire/ --\u00a0AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced today the publication of the paper, \" An update on GM-CSF and its potential role in melanoma management ,\"\u00a0in the journal Melanoma Management. Robert O. Dillman , M.D., chief medical officer at AIVITA, authored the article."
  },
  {
    "text":"Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital. - Biohaven's verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH. - Verdiperstat is a brain-penetrant inhibitor of myeloperoxidase (MPO), an enzyme implicated in neuroinflammatory and neurodegenerative disorders including ALS. NEW HAVEN, Conn. , Aug. 3, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (\"Biohaven\" or the \"Company\") announced today that the first patients were enrolled in the HEALEY ALS Platform Trial, which is evaluating the efficacy of three treatments including verdiperstat in people with amyotrophic lateral sclerosis (\"ALS\").\u00a0Verdiperstat is a potential first-in-class, brain-penetrant, selective inhibitor of myeloperoxidase in development by Biohaven for the treatment of neurodegenerative diseases, including ALS and multiple system atrophy."
  },
  {
    "text":"Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation Committee of Mirum\u2019s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 11,300 shares of common stock to one new employee under Mirum\u2019s 2020 Inducement Plan. The Compensation Committee of Mirum\u2019s Board of Directors approved the awards as an inducement material to the new employee\u2019s employment in accordance with Nasdaq Listing Rule 5635(c)(4)."
  },
  {
    "text":"Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia. Enzychem Lifesciences (KOSDAQ: 183490) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate its lead therapeutic candidate EC-18, in a Phase 2 clinical trial in patients with Acute Respiratory Disease Syndrome (ARDS) due to COVID-19 pneumonia. A Phase 2 study for EC-18 in Preventing ARDS due to novel coronavirus pneumonia is currently ongoing in South Korea."
  },
  {
    "text":"Celltrion to Launch Both Antigen and Antibody Testing Kits in the U.S. Celltrion plans to launch two rapid COVID-19 testing kits, SAMPINUTETM COVID-19 Antigen MIA for detection of SARS-CoV-2 antigen, and DiaTrustTM COVID-19 IgG/IgM Rapid Test for detection of SARS-CoV-2 IgG/IgM antibody in the US.\n\n\nBoth tests deliver fast and reliable results with over 90% sensitivity and specificity agreement. \n\n\nCelltrion USA, Inc., the US subsidiary of Celltrion, and exclusive distributor of Celltrion\u2019s small molecule and other injectable products will be marketing the test kits. Celltrion Group (KRX:068270) today announced the launch of two rapid kits for SARS-CoV-2 in the US by the third week of August."
  },
  {
    "text":"Personalis Announces Pricing of Public Offering of Common Stock. Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share. Gross proceeds to Personalis from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses."
  },
  {
    "text":"Mammography Equipment Market Analysis and Forecast 2015-2030 Featuring Siemens Healthineers, Philips Healthcare, Hologic, GE Healthcare, and Fujifilm Holdings Corporation - ResearchAndMarkets.com. The \"Mammography Equipment (Diagnostic Imaging) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Additional analysis of real-world data confirms sequential Gilotrif\u00ae followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC. - Median time on treatment for the sequence was 28.4 months overall and was similar across subgroups. - This new analysis of U.S. patient outcomes from the GioTag real-world sequencing study of patients with Del19/L858R EGFR mutation-positive NSCLC with acquired T790M mutations is published today in Future Oncology. RIDGEFIELD, Conn. , Aug. 10, 2020 /PRNewswire/ -- Boehringer Ingelheim today announced a new analysis from the GioTag study, which showed that sequential Gilotrif\u00ae (afatinib) and osimertinib contributed to a median overall survival (OS) of nearly four years (47.6 months) among U.S. patients (129) with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) and the common resistance mutation, T790M. These findings are consistent with the global primary analysis of the GioTag study, as well as a separate, interim U.S. analysis ."
  },
  {
    "text":"Global Doptelet (Avatrombopag) Industry to 2030 - Drug Insight and Market Forecast - ResearchAndMarkets.com. The \"Doptelet (Avatrombopag) - Drug Insight and Market Forecast - 2030\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Applied DNA Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton Tagging. - Newly allowed Patent Protects Methods of Tagging Cotton Fibers During Ginning Process -. Applied DNA Sciences, Inc. (NASDAQ: APDN) (\u201cApplied DNA\u201d or the \u201cCompany\u201d) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 14/572,552 (US 2016/0168781 A1) entitled \u201cMethod and Device for Marking Fibrous Materials.\u201d The allowed claims cover methods of DNA-tagging cotton fibers while they travel through the forced air systems found at cotton gins, and later authenticating the DNA-tagged cotton fibers to prove their provenance and/or authenticity all the way to finished goods. DTS units have tagged over 300 million pounds of cotton to-date."
  },
  {
    "text":"IMV Inc. Announces Second Quarter 2020 Financial Results. Rapidly progressing DPX-COVID-19, including Health Canada agreement on Phase 1 clinical study design protocol, with preliminary results expected in fall 2020\n\n\n\n\nConfirmed $4.75M of non-dilutive fund supporting Phase 1 clinical development of DPX-COVID-19 \n\n\n\n\nUpdated data from Phase 2 DeCidE1 study with a 26% clinical response rate highlighting the potential of DPX-Survivac to improve the standard of care in advanced ovarian cancer \n\n\n\n\nPro-forma cash and cash equivalents of $61.8M on June 30th, 2020\n\n\n\n\nManagement to host a conference call and webcast today at 8:00 a.m. ET. IMV Inc. (the \u201cCompany\u201d or \u201cIMV\u201d) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced financial results for the second quarter ended June 30, 2020 and provided an update on its clinical and operational progress."
  },
  {
    "text":"Bayer and Temasek Unveil Innovative New Company Focused on Developing Breakthroughs in Vertical Farming. Initial efforts will focus on innovating vegetable varieties that deliver optimized quality and sensory experience\n\n\nCalled Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore\n\n\nJohn Purcell appointed as CEO. Leaps by Bayer , the impact investment arm of Bayer AG and Temasek , the global investment company headquartered in Singapore, today announced the joint investment and formation of a new company, Unfold . The new venture will focus on innovation in vegetable varieties with the goal of lifting the vertical farming space to the next level of quality, efficiency and sustainability."
  },
  {
    "text":"Impact of COVID-19 on the Sigmoidoscopes Market, 2020-2030 - ResearchAndMarkets.com. The \"Sigmoidoscopes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Scholar Rock Announces that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular Atrophy. Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for SRK-015 for the treatment of Spinal Muscular Atrophy (SMA), a progressive, rare genetic disease that leads to motor function impairments. Scholar Rock is on track to report 6-month interim efficacy and safety data from the ongoing TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 SMA in the fourth quarter of 2020. Top-line data for the 12-month treatment period are expected in the first half of 2021."
  },
  {
    "text":"Omnicell to Acquire Pharmaceutical Strategy Group\u2019s Leading 340B Software-Enabled Service Business. Expands pharmacy supply chain capabilities for efficient, compliant management of 340B programs\n\n\nAccelerates Omnicell\u2019s strategic transformation to support the vision of the fully Autonomous Pharmacy, building on the recent launch of Omnicell One \n\n\nExpected to be immediately accretive to non-GAAP earnings per share. Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has entered into a definitive agreement with Pharmaceutical Strategies Group (PSG) to acquire its 340B Link business for total aggregate cash consideration of $225 million, subject to customary adjustments. The acquisition will add a comprehensive and differentiated suite of software-enabled services and solutions used by certain eligible hospitals, health systems, clinics, and entities to manage compliance and capture 340B drug cost savings on outpatient prescriptions filled through the eligible entity\u2019s pharmacy or a contracted pharmacy partner."
  },
  {
    "text":"Insights on the Wrist Replacement Market to 2030 - Analysis and Forecast Model - ResearchAndMarkets.com. The \"Wrist Replacement (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate. KIRKLAND, QC , and MAINZ, Germany , Aug. 5, 2020 /CNW/ - Pfizer Canada and BioNTech SE today announced an agreement with the Government of Canada to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and Health Canada approval."
  },
  {
    "text":"Neurovascular Thrombectomy Devices and COVID-19's Impact on the Industry, 2020-2030 - ResearchAndMarkets.com. The \"Neurovascular Thrombectomy Devices (Neurology Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist Pipeline Insight, 2020 - ResearchAndMarkets.com. The \"Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist - Pipeline Insight, 2020\" drug pipelines has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for \"Methods of Administering 3,4-Diaminopyridine\". -The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain mutations in each allele of the NAT2 gene. CORAL GABLES, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/128,672. The allowed application, \"Methods of Administering 3,4-Diaminopyridine\", claims a method of treating a human patient diagnosed with a 3,4-DAP sensitive disease by administering 3,4-DAP (or salts thereof) to slow acetylating patients having certain mutations in each allele of the NAT2 gene."
  },
  {
    "text":"Sight Sciences Announces First Patients Enrolled in ORION: A Prospective, Multicenter Clinical Trial of the OMNI Surgical System in Pseudophakic, Mild-to-Moderate Glaucoma Patients. Trial to Provide Surgeons with Prospective, Standalone Clinical Data on Microinvasive Glaucoma Surgery. MENLO PARK, Calif. , Aug. 10, 2020 /PRNewswire/ -- Sight Sciences, Inc. , a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the enrollment of the first patients in the ORION Clinical Study. The purpose of the study is to build upon the growing body of clinical evidence and accelerating commercial use of the OMNI \u00ae Surgical System in pseudophakic eyes (eyes which had previously undergone cataract surgery) by providing ophthalmic surgeons with prospective, multicenter clinical trial data from 10 sites across the United States ."
  },
  {
    "text":"Biodesix to Provide COVID-19 Testing for Colorado State University Campus. Biodesix Prepares to Test Thousands as Students Return to Campus. Biodesix, Inc. , a leading diagnostic company with a focus in lung disease, today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24."
  },
  {
    "text":"Omeros Announces Pricing of Public Offerings. --6,900,000 Shares of Common Stock--\n--$210,000,000 of 5.25% Convertible Senior Notes due 2026--. Omeros Corporation (Nasdaq: OMER) (\u201cOmeros\u201d) today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock (the \u201cShares\u201d) at a public offering price of $14.50 per Share for proceeds of approximately $100,050,000, prior to the deduction of underwriting discounts and commissions and estimated offering expenses payable by Omeros (the \u201cEquity Offering\u201d), and $210,000,000 aggregate principal amount of 5.25% convertible senior notes due 2026 (the \u201c2026 Convertible Notes\u201d and such offering, the \u201cNotes Offering\u201d). In addition, Omeros has granted to the underwriters of the Equity Offering a 30-day option to purchase up to an additional 1,035,000 Shares and to the underwriters of the Notes Offering a 30-day option, solely to cover over-allotments, to purchase up to an additional $31,500,000 aggregate principal amount of 2026 Convertible Notes. The Equity Offering and the Notes Offering are each expected to close on August 14, 2020, subject to customary closing conditions. Neither offering is contingent on the completion of the other offering."
  },
  {
    "text":"Tina Rogers named Senior Scientific Advisor at Sinclair Research. Sinclair Research, a leading provider of nonclinical research services, has named Dr. Tina Rogers, PhD, MBA, DABT as Senior Scientific Advisor. In this newly created role, Dr. Rogers will advise Sinclair\u2019s strategic direction, lead the expansion of Sinclair\u2019s nonclinical development services and provide scientific and regulatory guidance to support current and prospective customers."
  },
  {
    "text":"/C O R R E C T I O N -- JanOne/. In the news release, JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials, issued 11-Aug-2020 by JanOne over PR Newswire, we are advised by the company that the 1st paragraph, 1st sentence, should read \"[JAN101...] showed success in Phase 1 and Phase 2a trials [...]\" rather than \"[JAN101...] showed success in Phase 1 and Phase 2b trials [...]\" as originally issued inadvertently. The complete, corrected release follows:"
  },
  {
    "text":"Personal Emergency Response System Market Highlights the Impact of COVID-19 (2020-2024) | Growing Geriatric Population to Boost the Market Growth | Technavio. Technavio has been monitoring the personal emergency response system market and it is poised to grow by USD 2.47 billion during 2020-2024, progressing at a CAGR of 6% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment."
  },
  {
    "text":"Karuna Therapeutics Appoints Laurie Olson to Board of Directors. Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Laurie Olson to its Board of Directors effective August 12, 2020. Ms. Olson will be part of the nominating and corporate governance committee."
  },
  {
    "text":"New York Bariatric Group Reduces the Risk of Severe COVID-19 Outcomes in Overweight and Obese Patients. ROSLYN HEIGHTS, N.Y. , Aug. 11, 2020 /PRNewswire/ -- Preliminary studies have surfaced that being overweight or obese have been shown to increase the severity and rate of mortality in individuals with COVID-19. New York Bariatric Group started seeing an influx of patients seeking out options to get to a healthier weight following the COVID outbreak. The options available at New York Bariatric Group for rapid and successful long-term weight loss is a solution for obesity and provides a viable option for those seeking to reduce the health risks associated with contracting COVID-19."
  },
  {
    "text":"Contrast Induced Nephropathy: World Pipeline Report 2020 - ResearchAndMarkets.com. The \"Contrast Induced Nephropathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"NDA Partners in Conjunction with RJR Consulting and Intrinsik Supports Successful CTA Approval by Health Canada for First-in-Human Clinical Study. NDA Partners Chief Executive Officer Earle Martin announced today that its client, Asahi Kasei Pharma (AKP), has successfully received approval of their Clinical Trial Application (CTA) from Health Canada to conduct a first-in-human study for a new therapy for patients undergoing posterolateral fusion (PLF) surgery. The safety and efficacy of the therapy are still under investigation and market authorization has not yet been obtained in any country. NDA Partners in conjunction with RJR Consulting, Inc. served as Asahi Kasei Pharma's strategic regulatory advisor for the CTA submission. ROCHELLE, Va. , Aug. 12, 2020 /PRNewswire-PRWeb/ -- NDA Partners Chief Executive Officer Earle Martin announced today that its client, Asahi Kasei Pharma , has successfully received approval of their Clinical Trial Application (CTA) from Health Canada to conduct a first-in-human clinical study for a new therapy for patients undergoing posterolateral fusion (PLF) surgery. The safety and efficacy of the therapy are still under investigation and market authorization has not yet been obtained in any country. NDA Partners in conjunction with RJR Consulting, Inc. served as Asahi Kasei Pharma's strategic regulatory advisor and Intrinsik Corp. provided scientific and regulatory guidance into the preparation and electronic filing of the CTA submission."
  },
  {
    "text":"FDA Approves Two Emergency INDs for COVID-19 Outpatient Therapy. First Reported eIND Issued for Outpatient COVID-19 Therapy. MIAMI, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs)\u00a0for treating mild to moderate respiratory distress due to COVID-19."
  },
  {
    "text":"RedHill Biopharma\u2019s Phase 2/3 COVID-19 Study Approved in Mexico. The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites -- The global Phase 2/3 study has been approved in Mexico, the UK and Russia and is also under review in\u00a0Italy, Brazil and additional countries -- Enrollment in a parallel U.S. Phase 2 study in patients with severe COVID-19 is approximately 50% complete and is expected to be completed this month -- Potential submission of global emergency use applications planned as early as Q4/2020"
  },
  {
    "text":"Centex Studies-Lake Charles to be the Only Site in SWLA to Run AstraZeneca COVID Vaccine Clinical Trial. Centex Studies will need 1800 volunteers in the Lake Charles area beginning Mid-August. LAKE CHARLES, La. , Aug. 5, 2020 /PRNewswire/ -- AstraZeneca, a front-runner in the race for a COVID vaccine, recently announced that they would begin enrolling for their Phase II/III clinical trial in Mid-August. Centex Studies-Lake Charles is proud to announce that they have been selected as one of the few sites enrolling for this study. In fact, they are the only site in the Southwest Louisiana area participating in this study."
  },
  {
    "text":"Entera Bio to Present at BTIG\u2019s Virtual Biotechnology Conference. BOSTON\u00a0and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on\u00a0Monday, August 10, 2020\u00a0at\u00a012:30 p.m. EDT."
  },
  {
    "text":"FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation. SILVER SPRING, Md. , Aug. 12, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This is the second FDA-approved targeted treatment for patients with this type of mutation. Approximately 8% of patients with DMD have a mutation that is amenable to exon 53 skipping."
  },
  {
    "text":"DeltaTrak Enhances Its Cold Chain Restart Program to Help Customers Battle COVID-19. DeltaTrak\u00ae, a leading innovator of cold chain solutions, is enhancing its Cold Chain Restart Program to offer customers safer and more efficient methods to protect their employees and clients from the COVID-19 pandemic. The program was created to help companies reopen on a safe footing by providing access to critically needed PPE solutions. Following an extremely positive response, DeltaTrak has added the ThermoTrace Auto-Check Non-Contact Infrared Forehead Thermometer and Touchless Hand Sanitizer Dispenser to address the need for effective, contactless and hands-free options for temperature measurement and sanitization."
  },
  {
    "text":"CE Marking Received for Core European Product, DyeVert Power XT. Key Highlights\n\n\n\nOsprey Medical has received European CE Marking approval for the 2nd generation DyeVert Power XT device\n\n\nApproval of DyeVert Power XT (for automatic injection) means the full coronary angiography market is now available to Osprey\u2019s DyeVert franchise\n\n\nDevice is expected to be a core product in the product portfolio being commercialised by GE Healthcare \n\n\nPublication of clinical literature supporting effectiveness of Osprey DyeVert technology by renowned cardiologist in Europe (Dr Briguori)\n\n\nUpdate on GE Healthcare Strategic Alliance. Osprey Medical, Inc. (ASX:OSP) ( Osprey or the Company ) is pleased to announce that the Company has received CE Marking for the DyeVert Power XT 2 nd generation device."
  },
  {
    "text":"TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business Results. Enters into worldwide license agreement with UNION Therapeutics for its Thin Film Freezing technology in combination with niclosamide\n\n\nCloses on $25.9 million private financing to further advance its technology platform for inhalable drug products, vaccines, biologics and botanicals\n\n\nCompletes Phase 1 trial dosing for Voriconazole Inhalation Powder and begins Phase 1 trial for Tacrolimus Inhalation Powder\n\n\nConference call and live webcast scheduled for Thursday, August 13, 2020 at 4:30pm EDT. TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the first quarter ended June 30, 2020, as well as provided a business update on recent corporate and clinical developments. The Company will discuss its clinical, corporate and financial highlights on a conference call and live webcast, scheduled today, Thursday, August 13, 2020 at 4:30pm EDT."
  },
  {
    "text":"Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021. Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2021, which ended June 30, 2020."
  },
  {
    "text":"Worldwide Electrophysiology Catheters Industry to 2026 - by Product Type and End-user - ResearchAndMarkets.com. The \"Global Electrophysiology Catheters Market 2020-2026\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Global Infrared (IR) Thermometer Market to Surpass US$ 18.20 Billion by 2027, Says Coherent Market Insights (CMI). According to Coherent Market Insights, the global infrared thermometer market is estimated to be valued at US$ 11.43 billion in 2020 and is expected to exhibit a CAGR of 7.1% during the forecast period (2020-2027)."
  },
  {
    "text":"MedX Announces Issuance of Shares in Connection with Advertising Services Agreement. MedX Health Corp. (\u201cMedX\u201d) (TSX-V: MDX) announces that pursuant the agreement for an online marketing and awareness program through AGORACOM, that was announced in a Press Release dated June 1, 2020, it has settled the second payment to AGORACOM, in the amount of $13,560, by issuance on August 12, 2020, of 104,307 shares at an issue price of $0.13 per share. The issue price of the shares was determined by using the undiscounted closing price of the Shares of the Company on the TSX Venture Exchange on August 11, 2020, being the last trading day before the date of issuance. The shares were issued pursuant to the prospectus exemption contained in section 2.24 of National Instrument 45-106 Prospectus Exemptions, and are not subject to trading restrictions pursuant to the provisions of National Instrument 45-102, Resale of Securities since the criteria contained in NI 45-102 2.6(3) are met."
  },
  {
    "text":"Chugai\u2019s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder. A treatment option with a novel mechanism of action for anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder (NMOSD) approved in the U.S.\n\n\nEnspryng, the first approved drug applying Chugai\u2019s proprietary recycling antibody technology, allows patients with NMOSD to treat at home by self-injection* through subcutaneous administration every four weeks\n\n\nThe approval was granted based on the results from two global phase III studies where Enspryng showed significantly reduced risk of relapse in people with NMOSD. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has approved the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, Enspryng\u2122 (US generic name: satralizumab-mwge) (hereafter, Enspryng) created by Chugai for the treatment of adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). Enspryng is administered subcutaneously every four weeks ** . Enspryng was granted Breakthrough Therapy Designation in December 2018 and the US Biologics License Application (BLA) was filed in August 2019 by Genentech Inc. , a member of Roche Group."
  },
  {
    "text":"Cureatr, Inc. Announces the Appointment of its Strategic Advisory Board. Cureatr launches new clinical advisory board with four inaugural members to provide expertise, insight, and guidance to help set strategic direction. Cureatr, Inc. , a comprehensive medication management (CMM) technology and services company, today announced the creation of its Strategic Advisory Board (SAB) to provide external expertise, insight, and guidance to the company\u2019s management in regards to its business development, clinical strategy and direction, research and development activities and solution portfolio. The four inaugural members of Cureatr\u2019s SAB bring over a century of collective experience and expertise in several healthcare sectors including, health care information technology, managed care, informatics and outcomes measurement, quality improvement, CMS/HHS, employer health benefits, healthcare legislation and policy, retail pharmacy operations, reimbursement and M&A."
  },
  {
    "text":"bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D\u2122) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting. bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D\u2122) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including data from the Phase 2/3 Starbeam study (ALD-102) and available data from the Phase 3 ALD-104 study, will be presented at the 46 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2020), taking place virtually from August 29 - September 1, 2020."
  },
  {
    "text":"GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China. GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug candidate for liver fibrosis. The trial was a randomized, double-blind, placebo-controlled, multi-center, dose escalation study assessing the safety and efficacy of F351 for Hepatic Fibrosis in Chronic Viral Hepatitis B patients in China."
  },
  {
    "text":"Hawkeye Systems U.S.-Manufactured Masks Exceed 99% Filtration in ASTM Tests. SAVANNAH, Georgia , Aug. 17, 2020 /PRNewswire/ -- Hawkeye Systems, Inc. (OTCQB: HWKE), a technology holding company focused on pandemic management products and services, is pleased to announce an update on the progress of its partnership with DemeTECH, a U.S.-based manufacturer of suture and other medical devices and products. \"In this partnership we started with the creation of a surgical mask first, which has tested out as a level three ASTM mask, and once we (DemeTECH) got FDA approval for that mask, then turned to n95s which have been submitted for NIOSH approval,\" said Luis Arguello, Jr , SVP DemeTECH."
  },
  {
    "text":"PerkinElmer Enhances Hand Sanitizer Analyzer to Detect Methanol in 30 Seconds or Less. Instrument also tests ethanol and isopropanol concentrations to confirm product efficacy. PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its Hand Sanitizer Analyzer instrument can be used to test for the presence of methanol in alcohol-based hand sanitizer products with pass/fail results delivered in 30 seconds or less. Recent warnings and recalls from the FDA indicate that methanol can be toxic to consumers if absorbed through the skin and life threatening if ingested."
  },
  {
    "text":"Biomeme SARS-CoV-2 Test Approved by FDA Under Emergency Use Authorization. Biomeme's end-to-end SARS-CoV-2 Test uses gold standard Real-Time RT-PCR to assist in the diagnosis of COVID-19 in as little as an hour. PHILADELPHIA , Aug. 19, 2020 /PRNewswire-PRWeb/ -- Biomeme, Inc . announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme's SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures."
  },
  {
    "text":"Ancestry\u00ae Announces Free Six-Month Subscription for Teachers Just in Time for School Year. Access to Ancestry Library Edition Is Now Also Available as Free Remote Learning Resource for Parents and Tutors. Ancestry\u00ae, the global leader in family history and consumer genomics, announced today that for the first time, it will provide K-12 teachers across America a free six-month World Explorer subscription to access billions of historical records, providing support in lesson development and project creation for the school year ahead. Whether teaching in the classroom or through remote learning, Ancestry now offers free resources to inspire educators with new ways to engage students this fall."
  },
  {
    "text":"DJO\u00ae Introduces Two New EMPOWR\u2122 Systems Designed To Accelerate Surgical Efficiency. The EMPOWR Acetabular\u2122 System and EMPOWR Partial Knee\u2122 restore healthy kinematics and promote surgical efficiency with single-tray implantation. DJO, LLC (\u201cDJO\u201d or the \u201cCompany\u201d), a leading global provider of medical technologies to get and keep people moving, today announced two new EMPOWR\u2122 systems, EMPOWR Acetabular\u2122 and EMPOWR Partial Knee\u2122. Both systems were designed to restore healthy kinematics and optimize surgical procedure efficiencies by allowing implantation with a single tray."
  },
  {
    "text":"OncoNano Awarded $9.97 Million Grant from Cancer Prevention and Research Institute of Texas. Grant to support expanded application of lead product, ONM-100, for imaging metastatic disease that may have gone undetected. OncoNano Medicine, Inc. today announced that it has been awarded $9.97 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to expand the application of its lead product, ONM-100, an innovative imaging agent used in intraoperative surgical resection of solid tumors, for imaging metastatic disease."
  },
  {
    "text":"August Bioservices Launches New Brand Identity. New brand identity highlights expansion of capabilities and ambition to become a specialized, one-stop-shop CDMO for drug discovery, development and manufacturing services. August Bioservices , an emerging leader amongst contract development and manufacturing organizations (\u201cCDMOs\u201d) providing drug discovery, development, and manufacturing services, today revealed its new brand identity. The new brand launch follows August Bioservices\u2019 recent investment from Oak HC/FT and the appointment of several industry executives to its leadership team, which position the company to pursue strategic initiatives to grow the business."
  },
  {
    "text":"Clinical Informatics Startup Ovation.io Launches Pooled Testing to Bolster COVID-19 Offering and Support Return to Campus and Return to Work Initiatives. Pooling capability will allow more tests to be performed at a single time to meet COVID-19 testing demand, which will be a key element in supporting schools and large corporations to rapidly and efficiently test returning students and employees\n\n\nUniversity of Alabama at Birmingham utilizes Ovation\u2019s pooled COVID-19 testing. Ovation.io, Inc. (Ovation), makers of revolutionary solutions for molecular diagnostic labs, today announced support for pooled infectious disease testing, specifically COVID-19 testing, helping universities and large corporations to bring faculty, students and employees back to work safely and efficiently. This pooled testing builds on existing infrastructure being used by a growing network of labs currently testing for COVID-19 on an individual basis."
  },
  {
    "text":"LumiraDx Receives FDA Emergency Use Authorization for Point of Care COVID-19 Antigen Test. LONDON , Aug. 20, 2020 /CNW/ -- LumiraDx , the next-generation point of care diagnostic company, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the LumiraDx SARS-CoV-2 antigen test, which will help meet the global challenge of delivering fast and cost-efficient COVID-19 tests in community care settings. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application in symptomatic patients. In clinical studies, the LumiraDx SARS-CoV-2 antigen test demonstrated 97.6% positive agreement versus PCR in patients tested within 12 days of the onset of symptoms, making it the fastest, most sensitive antigen point of care test currently commercially available."
  },
  {
    "text":"2020 Orphan Diseases Pipeline Database - by Indication, Clinical Trial Phase, Drug Mechanism Classes & Company - ResearchAndMarkets.com. The \"Orphan Diseases Pipeline Database - 2020\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Global Phacoemulsification Market Outlook to 2027 with Profiles of Major Players Bausch Health Companies, Carl Zeiss Meditec, Alcon, Johnson & Johnson, Nidek Co, and Novartis - ResearchAndMarkets.com. The \"Global Phacoemulsification Market (By Products - Phacoemulsification Systems & Phacoemulsification Consumables; By Region - North America, Europe & Asia Pacific) Market Outlook 2027\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common stock as inducements to four newly-hired employees in connection with commencement of employment with the Company."
  },
  {
    "text":"Skechers Donates a Million Masks in Partnership With United Way of Greater Los Angeles and Charities. Masks Will Go to Communities in Need in the United States After Fans Dance to Hit Song \u201cSkechers\u201d by DripReport on TikTok\u2014A Track Shared More Than a Billion Times to Date. Skechers got the world dancing for a cause after dropping a TikTok dance challenge set to the track \u201cSkechers\u201d by DripReport that concluded with the lifestyle company donating one million masks to essential workers and communities in need. Skechers is partnering with the United Way of Greater Los Angeles and more charities across the country to deliver the masks directly to those who will most benefit."
  },
  {
    "text":"Romark Announces FDA Approval Of New Manufacturing Facility In Manati, Puerto Rico. TAMPA, Fla. , Aug. 20, 2020 /PRNewswire/ --\u00a0Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in Manati, Puerto Rico for the production of ALINIA \u00ae (nitazoxanide) tablets, 500 mg and ALINIA \u00ae (nitazoxanide) for Oral Suspension, 100 mg/5mL in the U.S. market."
  },
  {
    "text":"FDA approves Novartis Kesimpta\u00ae (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. - Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple sclerosis (RMS)\u00b9. - Approval based on two Phase III ASCLEPIOS studies demonstrating significant reductions in risk of relapses, confirmed disability progression, Gd+ T1 brain lesions and new/enlarging T2 lesions\u00b9. - In a post hoc analysis, 47.0% and 87.8% of patients treated with Kesimpta achieved no evidence of disease activity (NEDA-3) within the first (0-12 months) and second year (12-24 months) of treatment, respectively\u00b2. EAST HANOVER, N.J. , Aug. 20, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta\u00ae (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that has shown superior efficacy with a similar safety profile compared with teriflunomide and is a first-choice treatment option for RMS patients. 1 Kesimpta is the first B-cell therapy that can be self-administered once monthly at home via the Sensoready \u00ae autoinjector pen. 3"
  },
  {
    "text":"European Commission Approves KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older. \u2013 For the first time, up to 10,000 people in Europe ages 12 years and older with one F508del mutation and one minimal function mutation will be eligible for a medicine that treats the underlying cause of cystic fibrosis \u2013\n\n\n\u2013 People 12 years of age and older who have two F508del mutations will also be eligible for the new triple combination regimen \u2013. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission (EC) has granted marketing authorization for KAFTRIO \u00ae (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor to treat people with cystic fibrosis (CF) ages 12 years and older with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene."
  },
  {
    "text":"Humanigen Appoints Edward P. Jordan as Chief Commercial Officer. Mr. Jordan to build commercial infrastructure in advance of potential Emergency Use Authorization of lenzilumab. Humanigen, Inc. , (HGEN) (\u201cHumanigen\u201d), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called \u2018cytokine storm\u2019 with lenzilumab, the company\u2019s proprietary Humaneered \u00ae anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, today announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately."
  },
  {
    "text":"Global Influenza Diagnostics Market Outlook 2020-2026 - Influenza Testing Volumes Burgeoning due to the Outbreak of COVID-19 - ResearchAndMarkets.com. The \"Influenza Diagnostics Market by Test Type, by End-user, Geography - Forecast to 2026\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Veracyte Named a San Francisco Bay Area \u201cTop Workplace\u201d for Seventh Consecutive Year. Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has been awarded a Top Workplaces 2020 honor by the Bay Area News Group for the seventh consecutive year. The annual award is based solely on employee feedback gathered through an anonymous, third-party survey."
  },
  {
    "text":"North American Mobile Cardiac Telemetry Systems Market by Application, End User and Country (2020-2026) - ResearchAndMarkets.com. The \"North America Mobile Cardiac Telemetry Systems Market By Application (Lead based and Patch Based), By End User (Hospitals, Cardiac centers and Other End-user), By Country, Industry Analysis and Forecast, 2020 - 2026\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Azul3D Secures $12.5 Million in Seed Funding. Investment will support launch of record-breaking, high-throughput 3D printers. In the midst of the COVID crisis, Azul 3D TM continues to pick up steam."
  },
  {
    "text":"Insulet to Present at Upcoming Investor Conferences. Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod \u00ae Insulin Management System, today announced that management will present at three upcoming virtual investor conferences:"
  },
  {
    "text":"Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules. Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules."
  },
  {
    "text":"NewAmsterdam Pharma Acquires Obicetrapib from Amgen. AMG 899 or Obicetrapib to be developed by Netherlands-based company to be headed up by Dr. Michael Davidson and Dr. John Kastelein\n\n\nObicetrapib, a potent ApoB and LDL-c lowering small molecule drug, will be tested in patients not well controlled on statins and statin-intolerant patients\n\n\nPivotal Phase 3 studies in dyslipidemia planned to start in 2021. NewAmsterdam Pharma B.V. (\u201cNAP\u201d) has acquired the rights to obicetrapib (AMG 899) from Amgen."
  },
  {
    "text":"Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 IDHENTIFY study evaluating IDHIFA \u00ae (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint of overall survival (OS) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The safety profile of IDHIFA was consistent with previously reported findings. The company will complete a full evaluation of the IDHENTIFY data and work with investigators to present detailed results at a future medical meeting."
  },
  {
    "text":"Global Patient Monitoring Devices Market, Forecast to 2026 - ResearchAndMarkets.com. The \"Patient Monitoring Devices Market by Type, End User and Geography - Global Forecast to 2026\" report has been added to ResearchAndMarkets.com's offering."
  },
  {
    "text":"Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases. Collaboration combines Engitix\u2019s unique ECM platform with Takeda\u2019s expertise in gastroenterology research and development (R&D) and commercialisation. Engitix Ltd (\u2018Engitix\u2019), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company Limited (\u2018Takeda\u2019) to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH)."
  },
  {
    "text":"Harmony Biosciences To Present New Data For WAKIX\u00ae (pitolisant) At SLEEP 2020 Annual Meeting. Four poster presentations will feature clinically relevant efficacy and safety data analyses for WAKIX in adult patients with narcolepsy. PLYMOUTH MEETING, Pa. and CHICAGO , Aug. 24, 2020 /PRNewswire/ --\u00a0Harmony Biosciences Holdings, Inc. (\"Harmony\") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today it will present new data on the safety and efficacy of WAKIX\u00ae (pitolisant), including four poster presentations at the upcoming 34th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as \"SLEEP 2020.\" The meeting is being held virtually from August 27-30 . Abstracts of the WAKIX data will also be published in the journal SLEEP as an online supplement."
  },
  {
    "text":"MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD. MindMed is funding a Phase 1 Clinical Trial at University Hospital Basel Liechti Lab"
  },
  {
    "text":"Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease. Top-line data anticipated in 4Q2020 upon completion of final monitoring visits. "
  },
  {
    "text":"FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations. - Tepotinib granted Priority Review and is being evaluated under FDA Real-Time Oncology Review (RTOR) pilot program. - Tepotinib is a highly targeted inhibitor of c-MET that is administered as a once-daily oral tablet. - Data show robust, consistent and durable clinical response across different lines of therapy, including in patients with brain metastases, and as assessed by liquid biopsy or tissue biopsy. ROCKLAND, Mass. , Aug. 25, 2020 /PRNewswire/ --\u00a0EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada , today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the new drug application (NDA) for once-daily, orally-dosed tepotinib* for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 ( MET ex14) skipping, as detected by an FDA-approved test. Tepotinib was granted Priority Review and is being reviewed by the FDA under its Real-Time Oncology Review (RTOR) pilot program, which is intended to create a more efficient review process to bring safe and effective treatments to patients as early as possible. 1 Priority Review is intended to accelerate evaluation of applications for drugs that could offer improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. 2 Tepotinib was granted Breakthrough Therapy Designation by the FDA in September 2019 for\u00a0the treatment of patients with metastatic NSCLC harboring MET ex14 skipping alterations who progressed following platinum-based cancer therapy."
  },
  {
    "text":"Philips and B. Braun receive FDA clearance for breakthrough Onvision\u00ae Needle Tip Tracking technology for regional anesthesia. BETHLEHEM, Pa. , Aug. 25, 2020 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and B. Braun Medical Inc ., a global market leader 1 in regional anesthesia and pain management, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Onvision \u00ae , a breakthrough ultrasound guidance solution for real-time needle tip tracking. Available exclusively on the latest version of the B. Braun and Philips Xperius \u00ae ultrasound system together with the dedicated Stimuplex \u00ae Onvision needle,\u00a0Onvision gives anesthesiologists the confidence to accurately position the needle tip inside the body for Peripheral Nerve Blocks (PNBs)."
  },
  {
    "text":"New Study Finds Music & Memory Program Reduces Distressed Behavior and Decreases Need for Antipsychotic Medication in Dementia Patients. NEW YORK , Aug. 25, 2020 /PRNewswire/ -- In the most comprehensive study of its kind on the effects of the Music & Memory program, researchers from the Betty Irene Moore School of Nursing at UC Davis found that personalized music is associated with a reduction in the amount of antipsychotic medication taken by nursing home residents and fewer distressed behaviors. The results are published in the Journal for Post-acute and Long-term Care Medicine (JAMDA)"
  }
]